SFX by Ex Libris Inc.

Title:	Immunodeficiency, autoinflammation and amylopectinosis in humans with inherited HOIL-1 and LUBAC deficiency
Source:	Nature Immunology [1529-2908] Boisson, Bertrand yr:2012

Basic

Sorry, no full text available...

Please use the document delivery service (see below)

Holding information

Holdings in library search engine ALBERT

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Sato, Douglas K. "Aquaporin-4 antibody-positive cases beyond current diagnostic criteria for NMO spectrum disorders." Neurology 80.24 (2013): 2210-2216.
description	2.	Ombrello, Michael J. "HOIL and water: the two faces of HOIL-1 deficiency." Nature Immunology 13.12 (2012): 1133-1135.
description	3.	Speaker, Kristin J. "Interleukin-1 beta: a potential link between stress and the development of visceral obesity." BMC physiology 12.1 (2012): 8-8.
description	4.	GOEBEL, H. "Adult Polyglucosan Body Myopathy." Journal of neuropathology and experimental neurology 51.1 (1992): 24-35.
description	5.	Girschick, S. "Tumor necrosis factor receptor 1-associated periodic syndrome without fever: cytokine profile before and during etanercept treatment." Rheumatology international 30.2 (2009): 207-212.
description	6.	Wingerchuk, Claudia F G. "The spectrum of neuromyelitis optica." Lancet. Neurology 6.9 (2007): 805-15.
description	7.	"Antioxidant Protection of the Brain in Rats during Acute Stress and Administration of Interleukin-1β." Bulletin of experimental biology and medicine 153.5: 680-683.
description	8.	Lecron, S. "Brief Report: Involvement ofTNFRSF11AMolecular Defects in Autoinflammatory Disorders." Arthritis & rheumatology 66.9 (2014): 2621-2627.
description	9.	Knight, Jason S. "Peptidylarginine deiminase inhibition is immunomodulatory and vasculoprotective in murine lupus." The Journal of clinical investigation 123.7 (2013): 2981-2993.
description	10.	Gudmundsson, Larus S. "Migraine, depression, and brain volume: The AGES-Reykjavik Study." Neurology 80.23 (2013): 2138-2144.
description	11.	Jacob, A. "Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders." Journal of neurology, neurosurgery and psychiatry 84.8 (2012): 922-930.
description	12.	Patel. "Long-Term Risk of Incident Type 2 Diabetes and Measures of Overall and Regional Obesity: The EPIC-InterAct Case-Cohort Study (Overall and Regional Obesity and Incident Diabetes)." PLoS Medicine 9.6 (2012).
description	13.	Heitmann, R J F L. "Obesity: Lessons from evolution and the environment." Obesity reviews 13.10 (2012): 910-922.
description	14.	Montalban, A. "Value of NMO-IgG determination at the time of presentation as CIS." Neurology 78.20 (2012): 1608-11.
description	15.	Sollberger, G. "Caspase-4 Is Required for Activation of Inflammasomes." The journal of immunology 188.4 (2012): 1992-2000.
description	16.	Goldbach-Mansky, R. "Autoinflammatory Disease Reloaded: A Clinical Perspective." Cell 140.6 (2010): 784-790.
description	17.	Jeub, M. "[Polyglycosan body myopathy]." Nervenarzt 77.12 (2006): 1487-1491.
description	18.	Wingerchuk, D M M. "The clinical course of neuromyelitis optica (Devic's syndrome)." Neurology 53.5 (1999): 1107-14.
description	19.	Wingerchuk, D M M. "Revised diagnostic criteria for neuromyelitis optica." Neurology 66.10 (2006): 1485-1489.
description	20.	Ghezzi, A. "Clinical characteristics, course and prognosis of relapsing Devic's Neuromyelitis Optica." Journal of neurology 251.1 (2003): 47-52.